JPMorgan analyst James Gordon raised the firm’s price target on Genmab to DKK 3,600 from DKK 3,450 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab submits JNDA for epcoritamab to treat patients with R/R LBCL
- Genmab downgraded to Neutral at Citi with risk/reward ‘more balanced’ for 2023
- Genmab downgraded to Neutral from Buy at Citi
- Genmab to hold a virtual investor update
- Genmab announces results from multiple clinical trials evaluating epcoritamab